International Journal of Hematology-Oncology and Stem Cell Research 2017. 11(4):328-339.

Acute Myeloid Leukemia—Genetic Alterations and Their Clinical Prognosis
Francisco Alejandro Lagunas-Rangel, Venice Chávez-Valencia, Miguel Ángel Gómez-Guijosa, Carlos Cortés-Penagos


Acute myeloid leukemia (AML) is a group of hematological diseases, phenotypic and genetically heterogeneous, characterized by abnormal accumulation of blast cells in the bone marrows and peripheral blood. Its incidence rate is approximately 1.5 per 100,000 in infants younger than 1 year of age and 25 per 100,000 persons in octogenarians. Traditionally, cytogenetic markers are used to stratify patients in three risk categories: favorable, intermediate and unfavorable. However, the forecast stratification and the treatment decision for patients with normal karyotype shows difficulties due to the high clinical heterogeneity. The identification of several genetic mutations additional to classical molecular markers has been useful in identifying new entities. Nowadays, many different mutations and epigenetic aberrations have been implicated in the diagnostic, prognostic and treatment of AML. This review is focused on describing the most important molecular markers with implications for clinical practice.


AML, Mutations, Molecular marker, Cytogenetic, Risk groups

Full Text:



Estey E, Döhner H. Acute myeloid leukaemia. Lancet. 2006; 368(9550):1894-907.

Liesveld JL, Lichtman MA. Acute myelogenous leukemia. In: Kaushansky K, Lichtman MA, Prchal JT, et al., eds. Williams Hematology. 9th ed. United States of America: McGraw-Hill Education; 2016.

Thomas X. First contributors in the history of leukemia. World J Hematol. 2013; 2(3):62-70.

Freireich EJ, Wiernik PH, Steensma DP. The leukemias: A half-century of discovery. J Clin Oncol. 2014; 32(31):3463-9.

Rubnitz JE, Gibson B, Smith FO. Acute myeloid leukemia. Hematol Oncol Clin North Am. 2010; 24(1):35-63.

Nichol JN, Assouline S, Miller WH. The etiology of acute leukemia. In: Neoplastic Diseases of the Blood. New York, NY: Springer New York; 2013:177-198.

Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet. 2002; 3:179-98.

Takahashi S. Current findings for recurring mutations in acute myeloid leukemia. J Hematol Oncol. 2011; 4:36.

Chen SJ, Shen Y, Chen Z. A panoramic view of acute myeloid leukemia. Nat Genet. 2013; 45(6):586-7.

Iliakis G, Wang Y, Guan J, et al. DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene. 2003; 22(37):5834-47.

Kolachana P, Subrahmanyam VV, Meyer KB, et al. Benzene and its phenolic metabolites produce oxidative DNA damage in HL60 cells in vitro and in the bone marrow in vivo. Cancer Res. 1993; 53(5):1023-6.

Hiraku Y, Kawanishi S. Oxidative DNA damage and apoptosis induced by benzene metabolites. Cancer Res. 1996; 56(22):5172-8.

Pfeifer GP, Denissenko MF, Olivier M, et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 2002; 21(48):7435-51.

Super HJ, McCabe NR, Thirman MJ, et al. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood. 1993; 82(12):3705-11.

Estey E, Thall P, Kantarjian H, et al. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia. 1997;11(10):1661-4.

Lichtman MA. Obesity and the risk for a hematological malignancy: Leukemia, lymphoma, or myeloma. Oncologist. 2010; 15(10):1083-101.

Kumar V, Abbas AK, Aster JC. Enfermedades de los leucocitos, gang lioslinfáticos, bazo y timo. In: Robbins Y Cotran. Patología Estructural Y Funcional. 9th ed. Barcelona: Elsevier España, S.L.U.; 2015:579-628.

Marcucci G, Bloomfield CD. Acute Myeloid Leukemia. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson JL, Loscalzo J, eds. Harrison’s Principles of Internal Medicine. 19th ed. United States of America: McGraw-Hill Education; 2015:678-687.

Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015; 373(12):1136-52.

Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999; 341(14):1051-62.

Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100(7):2292-302.

Meyer SC, Levine RL. Translational implications of somatic genomics in acute myeloid leukaemia. Lancet Oncol. 2014;15(9):e382-94.

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman J, ed. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4a ed. Lyon: International Agency for Research on Cancer (IARC); 2008.

Thompson MA. Molecular genetics of acute leukemia. In: Greer JP, Foerster J, Rodgers GM, et al., eds. Wintrobe’s Clinical Hematology. 12th ed. Philadelphia: Lippincott Williams & Wilkins; 2009:1791-1807.

Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer. 2002; 2(7):502-13.

Puccetti E, Ruthardt M. Acute promyelocytic leukemia: PML/RARα and the leukemic stem cell. Leukemia. 2004; 18(7):1169-1175.

De Braekeleer E, Douet-Guilbert N, De Braekeleer M. RARA fusion genes in acute promyelocytic leukemia: A review. Expert Rev Hematol. 2014; 7(3):347-57.

Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007; 7(11):823-33.

Marschalek R. Mechanisms of leukemogenesis by MLL fusion proteins. Br J Haematol. 2011; 152(2):141-54.

De Braekeleer M, Le Bris MJ, De Braekeleer E, et al. 3q26/ EVI1 rearrangements in myeloid hemopathies: A cytogenetic review. Futur Oncol. 2015; 11(11):1675-86.

Martelli MP, Sportoletti P, Tiacci E, et al. Mutational landscape of AML with normal cytogenetics: Biological and clinical implications. Blood Rev. 2013; 27(1):13-22.

Meshinchi S, Appelbaum FR. Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res. 2009; 15(13):4263-9.

Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003; 3(9):650-65

Parcells BW, Ikeda AK, Simms-Waldrip T, et al. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia. Stem Cells. 2006; 24(5):1174-84.

Levis M. FLT3 mutations in acute myeloid leukemia: What is the best approach in 2013? Hematology Am Soc Hematol Educ Program. 2013; 2013: 220-6.

Chan PM. Differential signaling of Flt3 activating mutations in acute myeloid leukemia: A working model. Protein Cell. 2011; 2(2):108-15.

Griffith J, Black J, Faerman C, et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell. 2004; 13(2):169-78.

Grisendi S, Mecucci C, Falini B, et al. Nucleophosmin and cancer. Nat Rev Cancer. 2006; 6(7):493-505.

Burgess RJ, Zhang Z. Histone chaperones in nucleosome assembly and human disease. Nat Struct Mol Biol. 2013; 20(1):14-22.

Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): Association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005; 106(12):3747-54.

Falini B, Nicoletti I, Martelli MF, et al. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): Biologic and clinical features. Blood. 2007;109(3):874-85.

Falini B, Bolli N, Liso A, et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: Molecular basis and clinical implications. Leukemia. 2009;23(10):1731-43.

Falini B, Nicoletti I, Bolli N, et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica. 2007; 92(4):519-32.

Leroy H, Roumier C, Huyghe P, et al. CEBPA point mutations in hematological malignancies. Leukemia. 2005; 19(3):329-34.

Bienz M, Ludwig M, Leibundgut EO, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res. 2005; 11(4):1416-24.

Nerlov C. C/EBPalpha mutations in acute myeloid leukaemias. Nat Rev Cancer. 2004; 4(5):394-400.

Pabst T, Mueller BU. Complexity of CEBPA dysregulation in human acute myeloid leukemia. Clin Cancer Res. 2009; 15(17):5303-7.

Conway O’Brien E, Prideaux S, Chevassut T. The epigenetic landscape of acute myeloid leukemia. Adv Hematol. 2014; 2014: 103175.

Yang L, Rau R, Goodell MA. DNMT3A in haematological malignancies. Nat Rev Cancer. 2015; 15(3):152-63.

Shih AH, Abdel-Wahab O, Patel JP, et al. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012; 12(9):599-612.

Kantarjian H. Acute myeloid leukemia—Major progress over four decades and glimpses into the future. Am J Hematol. 2016; 91(1):131-45.

Estey EH. Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol. 2013; 88(4):318-27.

Sanz-Alonso MA, Carreras-Pons E. Enfermedades del sistemamieloide. In: Rovira-Tarrats M, Sanz-Caballer J, eds. Manual Práctico de Hematología Clínica. 5th ed. Molins de Rei, España: Editorial Antares; 2015:149-164.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.